ANTEGRENDevelopment and Marketing Collaboration Agreement • September 4th, 2003 • Elan Corp PLC • Pharmaceutical preparations • New York
AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENTDevelopment and Marketing Collaboration Agreement • March 25th, 2003 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
SECOND AMENDMENT TO THE RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC., A DELAWARE CORPORATION (“ONYX”), and WARNER-LAMBERT COMPANY, A DELAWARE CORPORATION (“WARNER”).Development and Marketing Collaboration Agreement • March 25th, 2003 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS SECOND AMENDMENT (“Second Amendment”) to the RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT (“Agreement”), having an effective date of July 31, 1997, between Onyx and Warner, which Agreement was first amended on August 2, 1999 to extend its term one year, is entered into and made effective March 1, 2000. Onyx and Warner may be referred to herein individually as “Party,” or collectively, as the “Parties.”
AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENTDevelopment and Marketing Collaboration Agreement • February 23rd, 2011 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
SECOND AMENDMENT TO THE AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC., A DELAWARE CORPORATION (“ONYX”), and WARNER-LAMBERT COMPANY, A DELAWARE CORPORATION (“WARNER”)Development and Marketing Collaboration Agreement • March 25th, 2003 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS SECOND AMENDMENT (“Second Amendment”) between Onyx and Warner, which Agreement was amended and restated July 1997, the AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT as amended by that certain Amendment dated December 15, 1997 (as amended, the “Agreement”), dated as of May 2, 1995, is entered into and made effective March 1, 2000. Onyx and Warner may be referred to herein individually as “Party,” or collectively, as the “Parties.”
CONFIDENTIAL AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT DATED AS OF MAY 2, 1995 BETWEEN ONYX PHARMACEUTICALS, INC. AND WARNER-LAMBERT COMPANY TABLE OF CONTENTSDevelopment and Marketing Collaboration Agreement • November 14th, 1997 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
